All In Biotech

Drug Trial Radar · NCT06080776

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Last checked: Nov 19, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

242

Planned (sponsor's estimate)

Start

May 11, 2023

Primary completion

Feb 1, 2028

Study completion Feb 1, 2031

Sponsor

Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • SH-1028 tabletsDrug

    The initial dose of SH-1028 tablets is 200 mg once daily.

  • Placebo SH-1028 tabletsDrug

    Placebo SH-1028 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival (DFS) assessed by Independent Review Committee (IRC)Time frame: From the time of randomization to the recurrence of tumor or death, through study completion, an average of 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.